Apellis Pharmaceuticals, Inc. (APLS) reported $146.38 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 546$0.73 for the same period compares to -$1.50 a year ago.The reported revenue compares to the Zacks Consensus Estimate of$146.43 million, representing a surprise of -0.03%. The company delivered an EPS surprise of -10.61%, with the consensus EPS estimate being -$0.66.While investors closely watch year-over-year changes in headline numbers -- re ...